AVALO THERAPEUTICS, INC. (AVTX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -91.36M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-91.36M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-79.16M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-72.92M | $59.00K | (m) | (m) | (m) | -123601.69% |
| 2025-09-30 | $-66.49M | $192.00K | (m) | (m) | (m) | -34632.29% |
| 2025-06-30 | $-60.16M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-50.41M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-68.51M | $441.00K | (m) | (m) | (m) | -15535.60% |
| 2024-09-30 | $-62.86M | $820.00K | $-674.00K | (m) | (m) | -7665.73% |
| 2024-06-30 | $-53.75M | $807.00K | $288.00K | (m) | (m) | -6660.35% |
| 2024-03-31 | $-51.33M | $1.45M | $653.00K | (m) | (m) | -3542.17% |
| 2023-12-31 | $-27.35M | $1.92M | $1.28M | (m) | $10.30M | -1421.57% |
| 2023-09-30 | $-28.55M | $2.25M | $2.13M | (m) | (m) | -1269.36% |
| 2023-06-30 | $-20.70M | $16.96M | $2.41M | (m) | (m) | -122.06% |
| 2023-03-31 | $-25.38M | $17.35M | $3.27M | (m) | (m) | -146.25% |
| 2022-12-31 | $-37.44M | $18.05M | $3.43M | (m) | (m) | -207.41% |
| 2022-09-30 | $-46.55M | $17.37M | $3.24M | (m) | (m) | -267.92% |
| 2022-06-30 | $-67.11M | $3.77M | $3.62M | (m) | (m) | -1777.64% |
| 2022-03-31 | $-72.41M | $6.10M | $2.13M | (m) | (m) | -1187.39% |
| 2021-12-31 | $-82.13M | $5.40M | $1.49M | (m) | (m) | -1521.56% |
| 2021-09-30 | $-80.51M | $6.68M | $1.15M | (m) | (m) | -1206.03% |
| 2021-06-30 | $-77.32M | $6.44M | $315.20K | (m) | (m) | -1201.50% |
| 2021-03-31 | $-72.01M | $4.42M | $311.20K | (m) | (m) | -1630.07% |
| 2020-12-31 | $-72.84M | $6.70M | $300.20K | (m) | (m) | -1087.43% |
| 2020-09-30 | $-62.23M | $5.78M | $-3.59M | (m) | (m) | -1075.99% |
| 2020-06-30 | $-51.81M | $6.87M | $321.74K | (m) | (m) | -753.77% |
| 2020-03-31 | $-42.54M | $6.93M | $-1.25M | (m) | (m) | -614.12% |
| 2019-12-31 | $-16.14M | $6.75M | $-566.52K | (m) | (m) | -239.06% |
| 2019-09-30 | $-22.21M | $20.46M | $5.32M | (m) | (m) | -108.55% |
| 2019-06-30 | $-42.81M | $18.92M | $7.00M | (m) | (m) | -226.25% |
| 2019-03-31 | $-42.58M | $19.26M | $8.56M | $7.54M | (m) | -221.14% |
| 2018-12-31 | $-39.31M | $18.33M | $7.48M | $5.79M | (m) | -214.52% |
| 2018-09-30 | $-37.82M | $15.58M | (m) | (m) | (m) | -242.78% |
| 2018-06-30 | $8.33M | $36.54M | (m) | $5.66M | (m) | 22.81% |
| 2018-03-31 | $12.30M | $27.82M | (m) | $5.07M | (m) | 44.21% |
| 2017-12-31 | $13.89M | $27.81M | (m) | $4.37M | (m) | 49.94% |
| 2017-09-30 | $16.56M | (m) | (m) | $3.18M | (m) | (m) |
| 2017-06-30 | $-11.32M | (m) | (m) | $6.80M | (m) | (m) |
| 2017-03-31 | $-13.04M | (m) | (m) | $8.81M | (m) | (m) |
| 2016-12-31 | $-16.08M | (m) | (m) | $10.15M | (m) | (m) |
| 2016-09-30 | $-18.07M | (m) | (m) | $11.13M | (m) | (m) |
| 2016-06-30 | $-14.06M | (m) | (m) | $7.78M | (m) | (m) |
| 2016-03-31 | $-13.47M | (m) | (m) | $7.16M | (m) | (m) |
| 2015-12-31 | $-11.01M | (m) | (m) | $6.59M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | $10.23M | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | $11.21M | (m) | (m) |
| 2014-12-31 | $-17.12M | (m) | (m) | $12.24M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-12.93M | (m) | (m) | $8.91M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |